<DOC>
	<DOCNO>NCT00733850</DOCNO>
	<brief_summary>Gemcitabine usually use treat cancer pancreas . The purpose study determine Kanglaite Injection ( KLT ) safe patient cancer pancreas , whether improves effectiveness gemcitabine . Additionally , effect , , KLT sign symptom cancer well common side effect chemotherapy evaluate . The research drug , KLT , purify traditional Chinese medicine call coix seed . It approve China use combination chemotherapy treat patient advance lung cancer liver cancer . It also approve China use treat symptom cancer patient advance cancer kind . In US , KLT purely experimental approve use . While small number cancer patient US receive KLT alone Phase I study , first US protocol evaluate whether KLT useful pancreatic cancer . This phase II clinical study complete US June 2014 . The clinical study report submit FDA January 2015 . The designs phase III clinical study KLT clear FDA May 2015 launch soon .</brief_summary>
	<brief_title>Safety Exploratory Efficacy Kanglaite Injection Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Must life expectancy least 84 day ( 12 week ) Must ambulatory either Karnofsky performance status 60 high ECOG performance status 0 , 1 2 Must histologically confirm pancreatic cancer , either locally invasive metastatic , amenable potentially curative resection Must measurable evaluable target lesion , RECIST 1.1 criterion Must previously receive chemotherapy metastatic disease If female , must negative pregnancy test , least one year post menopausal , undergone surgical sterilization must willing use appropriate birth control measure unless post menopausal post surgical sterilization Must judge Investigator initiative mean compliant protocol include return followup visit schedule Must give write informed consent prior test protocol Must Hemoglobin &gt; 9 gm/dl , WBC &gt; 2 x109/ml , platelet &gt; 100,000/ul Must Alkaline Phosphatase &lt; 2.5 x ULN , ALT &lt; 2.0 x ULN , AST &lt; 2.0 x ULN bilirubin &lt; 2.0 Must stable renal function appropriate age . A patient must serum creatinine &lt; 1.5mg/dl GFR &gt; 60 mL/minute Must central venous catheter randomize G + K arm study , patient one , must agree one place randomize G+K arm . Patient history cancer within 5 year pancreatic cancer ( exclude resect non melanoma skin carcinoma Patient active ( untreated still receive corticosteroid ) brain metastasis Patient prior chemotherapy metastatic disease Patient receive prior gemcitabine &lt; 12 month previously Patient currently take bile acid sequestrant drug ( Questran , Colestid Welchol ) fibric acid derivative drug ( Lopid , Tricor , Antara , Lofibra Trilipix ) Patients disturbances lipid metabolism pathologic hyperlipidemia ( include congenital hypertriglyceridemia cholesterolemia ) , lipoid nephrosis , acute pancreatitis Patient uncontrolled Type 1 2 diabetes mellitus Patient another active medical condition ( ) organ disease ( ) may either compromise patient safety interfere safety and/or outcome ( e.g. , survival ) evaluation study drug Patient physician plan surgical treatment malignancy , radiation therapy , biological treatment cancer include immunotherapy study , surgical bypass stent insertion relief bile flow blockage Patient know allergy soybean ( use production Kanglaite Injection ) Job 's Tear ( source active ingredient Kanglaite Injection ) , gemcitabine Patient NYHA congestive heart failure Class II high cause Patient unstable angina history MI within 12 month Patient pregnant lactating Patient use plan use another investigational agent within four week prior screen entire study period include study termination followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>